Compare LAW & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | PRTC |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 386.7M |
| IPO Year | 2021 | N/A |
| Metric | LAW | PRTC |
|---|---|---|
| Price | $7.76 | $16.64 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 204.1K | 1.8K |
| Earning Date | 02-19-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $152,677,000.00 | $6,391,000.00 |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $8.39 | N/A |
| P/E Ratio | ★ N/A | $8.02 |
| Revenue Growth | 6.33 | ★ 1265.60 |
| 52 Week Low | $3.31 | $13.30 |
| 52 Week High | $9.11 | $20.00 |
| Indicator | LAW | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 48.09 |
| Support Level | $7.73 | $16.72 |
| Resistance Level | $8.33 | $16.99 |
| Average True Range (ATR) | 0.27 | 0.40 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 5.52 | 30.88 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.